Immune-stimulating monoclonal antibodies against human interleukin-2
AssigneeUniversitäT ZüRich
InventorsOnur Boyman, Natalia Arenas-Ramirez, Chao Zou
Life of this patent
Estimating the term…
Abstract
The invention relates to a human Interleukin-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)≤7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)≤1×10−4 s−1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.
Claims25
A human interleukin-2 (hIL-2) specific monoclonal antibody (mAb), or a hIL-2 specific antigen binding fragment thereof comprising a heavy chain complementarity determining region (HCDR) HCDR1 according to SEQ ID NO:
- 7, HCDR2 according to SEQ ID NO:
- 8, HCDR3 according to SEQ ID NO:
- 9, a light chain complementarity determining region (LCDR) LCDR1 according to SEQ ID NO:
- 10, LCDR2 according to SEQ ID NO:
- 11, LCDR3 according to SEQ ID NO:
- 12, wherein binding of said antibody, or antigen binding fragment thereof, to hIL-2 inhibits binding of hIL-2 to CD25.
A therapeutic formulation comprising a fusion protein and a pharmaceutically acceptable carrier, wherein said fusion protein comprises:
- a. an hIL-2 binding polypeptide fragment comprising HCDR1 according to SEQ ID NO:
- 7, HCDR2 according to SEQ ID NO:
- 8, HCDR3 according to SEQ ID NO:
- 9, LCDR1 according to SEQ ID NO:
- 10, LCDR2 according to SEQ ID NO:
- 11, LCDR3 according to SEQ ID NO:
- 12, wherein the hIL-2 binding polypeptide fragment binds to hIL-2 and inhibits the binding of hIL-2 to CD25,
- b. a human IL-2 polypeptide fragment having an identity of ≥90% compared to SEQ ID NO 001, and, optionally,
- c. an amino acid linker of 1 to 50 amino acids, linking the hIL-2 binding polypeptide fragment to the human IL-2 polypeptide fragment as one single polypeptide chain.
Dependencies are inferred from the claim text.